Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx^TM System for Chronic Bronchitis

Menlo Park, CA Sept. 16, 2019 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FDA) for the RheOx^TM Bronchial Rheoplasty^TM system.

…

Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx^TM System for Chronic Bronchitis

First-of-its-kind RheOx device designed to reduce mucus-producing cells and improve quality of life 

Menlo Park, CA Sept. 4, 2019 – Gala Therapeutics, Inc. (Gala) today announced that its RheOx^TM system has received CE Mark in the European Union.

…

Initial Study of the Minimally Invasive RheOx^TM Device Demonstrates Positive Results for Chronic Bronchitis Patients

Dallas, Texas, May 22, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced new results from the initial study of its investigational RheOx^TM device,

…

New Data from First-in-Human Study of RheOx^TM Device-Based Therapy for Chronic Bronchitis to be Presented at ATS 2019

Menlo Park, Calif., May 16, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from the first-in-human study of its investigational RheOx^TM device will be presented at the 2019 American Thoracic Society (ATS) International Conference,

…

Gala Enrolls First Subject at Temple Lung Center as Part of the US Early Feasibility Trial of RheOx^TM for Chronic Bronchitis in the United States

Menlo Park, Calif, November 5, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first patient at Temple Lung Center in Philadelphia,

…

Pittsburgh’s KDKA Publishes Story on the First Patient Treated with RheOx^TM in the United States

…

Gala Enrolls First Subjects in an Early Feasibility Study of RheOx^TM for Chronic Bronchitis in the United States

Menlo Park, Calif, November 5, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first two patients in the Early Feasibility Study of RheOx^TM for Chronic Bronchitis were treated at University of Pittsburgh Medical Center (UPMC) in Pittsburgh,

…

Gala Presents Positive Results from First-In-Human Clinical Trial of RheOx^TM in Chronic Bronchitis at the European Respiratory Society

• Favorable safety profile
• RheOx treatment resulted in clinical improvement as measured by Quality of Life scores, with treatment effect maintained at 12-month follow-up
• Improvement in airway biopsies and imaging

Menlo Park,

…

Data From First-In-Human RheOx^TM Bronchial Rheoplasty Trial to be Presented at the European Respiratory Society

Menlo Park, Calif, August 8, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from a Late-Breaking Abstract from a first-in-human study of the Rheox^TM system will be presented at the European Respiratory Society (ERS) in Paris,

…

Gala Therapeutics Receives FDA IDE Approval for a US Early Feasibility Study of Its RheOx^TM System to Treat Chronic Bronchitis

Menlo Park, Calif, July 12, 2018 – Gala Therapeutics (Gala) today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to conduct an Early Feasibility Study (EFS) to examine the safety of the RheOx^TM system in subjects with Chronic Bronchitis. 

…